NASDAQ:EYEG - Eyegate Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.5990 -0.01 (-1.64 %)
(As of 07/22/2018 12:39 PM ET)
Previous Close$0.5990
Today's Range$0.58 - $0.6299
52-Week Range$0.29 - $1.42
Volume181,999 shs
Average Volume282,042 shs
Market Capitalization$25 million
P/E Ratio-0.59
Dividend YieldN/A
Eyegate Pharmaceuticals logoEyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds/defects and epitheliopathies, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body, as well as Eyegate II drug delivery system. The company has license agreements with the University of Miami and its School of Medicine; subsidiaries of Valeant Pharmaceuticals International, Inc.; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.

Receive EYEG News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio1.18
Quick Ratio1.18


Trailing P/E Ratio-0.59
Forward P/E Ratio-1.62
P/E GrowthN/A

Sales & Book Value

Annual Sales$410,000.00
Price / Sales60.98
Cash FlowN/A
Price / CashN/A
Book Value($0.11) per share
Price / Book-5.45


EPS (Most Recent Fiscal Year)($1.02)
Net Income$-13,210,000.00
Net MarginsN/A
Return on Equity-653.57%
Return on Assets-93.74%


Outstanding Shares41,740,000
Market Cap$25.00

Eyegate Pharmaceuticals (NASDAQ:EYEG) Frequently Asked Questions

What is Eyegate Pharmaceuticals' stock symbol?

Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

How were Eyegate Pharmaceuticals' earnings last quarter?

Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) released its quarterly earnings data on Friday, May, 11th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.24) by $0.10. The specialty pharmaceutical company earned $1.10 million during the quarter, compared to analysts' expectations of $0.49 million. View Eyegate Pharmaceuticals' Earnings History.

What price target have analysts set for EYEG?

1 Wall Street analysts have issued twelve-month price targets for Eyegate Pharmaceuticals' shares. Their predictions range from $3.00 to $3.00. On average, they anticipate Eyegate Pharmaceuticals' share price to reach $3.00 in the next twelve months. This suggests a possible upside of 400.8% from the stock's current price. View Analyst Ratings for Eyegate Pharmaceuticals.

What is the consensus analysts' recommendation for Eyegate Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyegate Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Eyegate Pharmaceuticals' key competitors?

Who are Eyegate Pharmaceuticals' key executives?

Eyegate Pharmaceuticals' management team includes the folowing people:
  • Mr. Stephen From, Pres, CEO & Director (Age 55)
  • Dr. Barbara M. Wirostko, Chief Medical Officer (Age 52)
  • Mr. Michael P. Manzo, VP of Engineering (Age 59)
  • Ms. Sarah Romano, Chief Financial Officer
  • Mr. Paul Perkins, Sr. Director of Fin. & HR and Director of Fin.

When did Eyegate Pharmaceuticals IPO?

(EYEG) raised $5 million in an initial public offering on Friday, February 13th 2015. The company issued 800,000 shares at $6.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO.

Has Eyegate Pharmaceuticals been receiving favorable news coverage?

Media stories about EYEG stock have trended somewhat negative this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eyegate Pharmaceuticals earned a media sentiment score of -0.10 on Accern's scale. They also gave press coverage about the specialty pharmaceutical company an impact score of 45.02 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Eyegate Pharmaceuticals' major shareholders?

Eyegate Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include ARMISTICE CAPITAL, LLC (40.20%) and ARMISTICE CAPITAL, LLC (50.80%). Company insiders that own Eyegate Pharmaceuticals stock include Armistice Capital Master Fund, Morton Goldberg, Sarah Romano and Stephen From. View Institutional Ownership Trends for Eyegate Pharmaceuticals.

How do I buy shares of Eyegate Pharmaceuticals?

Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eyegate Pharmaceuticals' stock price today?

One share of EYEG stock can currently be purchased for approximately $0.5990.

How big of a company is Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals has a market capitalization of $25 million and generates $410,000.00 in revenue each year. The specialty pharmaceutical company earns $-13,210,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Eyegate Pharmaceuticals employs 17 workers across the globe.

How can I contact Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869.

MarketBeat Community Rating for Eyegate Pharmaceuticals (NASDAQ EYEG)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  191 (Vote Outperform)
Underperform Votes:  94 (Vote Underperform)
Total Votes:  285
MarketBeat's community ratings are surveys of what our community members think about Eyegate Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYEG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.